Given that the nuclear localization of FBP1 is critical for modulating the sensitivity to the PARP inhibitors, as described above, we aimed to evaluate the effect of the FBP1‐K206R mutant on the response of pancreatic cancer to PARP inhibitors. The gene discussed is FBP1; the disease is pancreatic neoplasm.